Disc Medicine Posts $1.54 Q2 Loss Per Share, Wider Than Expected
IRON sits 85% above its 52-week low of $40.
Summary
Disc Medicine reported a Q2 loss of $1.54 per share, wider than the consensus estimate of around $1.20, with a net loss of $59.5 million. The wider loss reflects increased R&D spending as the company advances bitopertin following the FDA's Complete Response Letter in May. The company expects to submit its CRL response and receive an FDA decision by mid-2027. Cash runway extends into 2029, but the burn rate is accelerating, following a Q1 net loss of $1.10 per share and a recent $30 million drawdown from Hercules Capital. The next major catalyst is the Phase 3 data readout for bitopertin, expected in late 2026 or early 2027.
At the time of this announcement, IRON was trading at $73.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $40.00 to $99.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.